Betulinic acid binding to human serum albumin: A study of protein conformation and binding affinity

He, 1992, Atomic structure and chemistry of human serum albumin, Nature, 358, 209, 10.1038/358209a0 Curry, 1998, Crystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding sites, Nature Struct. Biol., 5, 827, 10.1038/1869 Curry, 1999, Atomic structure and chemistry of human serum albumin, Biochim. Biophys. Acta, 1441, 131, 10.1016/S1388-1981(99)00148-1 Sugio, 1999, Crystal structure of human serum albumin at 2.5Å resolution, Protein Eng., 12, 439, 10.1093/protein/12.6.439 Bhattacharya, 2000, Crystallographic analysis reveals common modes of binding of medium and long-chain fatty acids to human serum albumin, J. Mol. Biol., 303, 721, 10.1006/jmbi.2000.4158 Petitpas, 2001, Crystal structure of human serum albumin complexed with monounsaturated and polyunsaturated fatty acids, J. Mol. Biol., 314, 955, 10.1006/jmbi.2000.5208 Ghuman, 2005, Structural basis of the drug-binding specificity of human serum albumin, J. Mol. Biol., 353, 38, 10.1016/j.jmb.2005.07.075 Beauchemin, 2007, Polyamine analogues bind human serum albumin, Biomacromolecules, 8, 3177, 10.1021/bm700697a Kanakis, 2007, Crocetin, dimethylcrocetin, and safranal bind human serum albumin: stability and antioxidative properties, J. Agric. Food Chem., 55, 970, 10.1021/jf062638l N’soukpoe-Kossi, 2007, Retinol and retinoic acid bind human serum albumin: stability and structural features, Int. J. Biol. Macromol., 40, 484, 10.1016/j.ijbiomac.2006.11.005 Segre, 1974, Naproxen-aspirin interaction in man, Clin. Pharmacol. Ther., 15, 374, 10.1002/cpt1974154374 Aronson, 1980, Clinical pharmacokinetics of digoxin, Clin. Pharmacokinet., 5, 137, 10.2165/00003088-198005020-00002 Jackson, 1982, Altered plasma drug binding in cancer: role of alpha-i-acid glycoprotein and albumin, Chin. Pharmacol. Ther., 32, 295, 10.1038/clpt.1982.163 Van Peer, 1981, Binding of drugs in serum, blood cells and tissues of rabbits with experimental acute renal failure, Pharmacology, 22, 146, 10.1159/000137483 McKichan, 1990, Influence of protein binding and use of unbound (free) drug concentrations, 5 Pisha, 1995, Discovery of betulinic acid as a selective inhibitor of human melanoma that functions by induction of apoptosis, Nat. Med., 1, 1046, 10.1038/nm1095-1046 Cichewicz, 2004, Chemistry, biological activity, and chemotherapeutic potential of betulinic acid for the prevention and treatment of cancer and HIV infection, Med. Res. Rev., 24, 90, 10.1002/med.10053 Chowdhury, 2002, Betulinic acid, a potent inhibitor of eukaryotic topoisomerase I: identification of the inhibitory step, the major functional group responsible and development of more potent derivatives, Med. Sci. Monitor, 8, 254 Ganguly, 2007, Betulinic acid, a catalytic inhibitor of topoisomerase I, inhibits reactive oxygen species-mediated apoptotic topoisomerase I-DNA cleavable complex formation in prostate cancer cells but does not affect the process of cell death, Cancer Res., 67, 11848, 10.1158/0008-5472.CAN-07-1615 Rajendran, 2008, Pharmacological evaluation of C-3 modified betulinic acid derivatives with potent anticancer activity, Invest New Drugs, 26, 25, 10.1007/s10637-007-9081-4 Chatterjee, 2000, Biotransformation of the antimelanoma agent betulinic acid by bacillus megaterium ATCC 13368, Appl. Environ. Microbiol., 66, 3850, 10.1128/AEM.66.9.3850-3855.2000 Kouzi, 2000, Microbial transformations of the antimelanoma agent Betulinic acid, J. Nat. Prod., 63, 1653, 10.1021/np000343a Akihisa, 2002, Microbial transformations of two lupane-type triterpenes and antitumor-promoting effects of the transformation products, J. Nat. Prod., 65, 278, 10.1021/np010424m Lewis, 1998, Molecular modeling of human CYP2C subfamily enzymes CYP2C9 and CYP2C19: rationalization of substrate specificity and sitedirected mutagenesis experiments in the CYP2C subfamily, Xenobiotica, 28, 235, 10.1080/004982598239542 Li, 2003, PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing, Proc. Natl. Acad. Sci. USA, 100, 13555, 10.1073/pnas.2234683100 Zhou, 2004, Pharmacologic inhibition of HIV-1 replication by a novel mechanism: specific interference with the final step of virion maturation, J. Virol., 78, 922, 10.1128/JVI.78.2.922-929.2004 Ahmad, 2006, Effect of albumin conformation on the binding of ciprofloxacin to human serum albumin: a novel approach directly assigning binding site, Biomacromolecules, 7, 1350, 10.1021/bm050996b He, 2006, Molecular modeling and spectroscopic studies on the binding of guaiacol to human serum albumin, J. Photochem. Photobiol. A Chem., 182, 158, 10.1016/j.jphotochem.2006.02.004 Sen, 2008, Formation of a molten globule like state in bovine serum albumin at alkaline, Eur. J. Biophys., 37, 1303, 10.1007/s00249-008-0335-7 Sinha, 2008, Temperature-dependent simultaneous ligand binding in human serum albumin, J. Phys. Chem. B, 112, 4884, 10.1021/jp709809b Bhattacharya, 1994, Interaction of chlorpromazine with mioglobin and hemoglobin. A comparative study, Biochem. Pharmacol., 47, 2049, 10.1016/0006-2952(94)90080-9 Kragh-Hansen, 1990, Structure and ligand binding properties of human serum albumin, Dan. Med. Bull., 37, 57 Dufour, 2005, Flavonoid-serum albumin complexation: determination of binding constants and binding sites by fluorescence spectroscopy, Biochim. Biophys. Acta, 1721, 164, 10.1016/j.bbagen.2004.10.013 Jiang, 2008, Design, synthesis and spectroscopic studies of resveratrol aliphatic acid ligands of human serum albumin, Bioorg. Med. Chem., 16, 6406, 10.1016/j.bmc.2008.05.002